Skip to main content
Clinical Trials/NCT04060680
NCT04060680
Completed
Not Applicable

Extravascular ICD Pivotal Study (EV ICD)

Medtronic Cardiac Rhythm and Heart Failure56 sites in 11 countries393 target enrollmentSeptember 16, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Tachycardia
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Enrollment
393
Locations
56
Primary Endpoint
Efficacy Outcome - Defibrillation Efficacy at Implant of the EV ICD System
Status
Completed
Last Updated
last year

Overview

Brief Summary

Pivotal Summary:

The study is designed to demonstrate safety and efficacy of the Extravascular Implantable Cardioverter Defibrillator (EV ICD) System.

Continued Access Summary:

This study is designed to provide continued access to the Extravascular Implantable Cardioverter Defibrillator (EV ICD) System.

Detailed Description

The study will enroll subjects who are indicated to receive an implantable defibrillator and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system, in which a lead is placed outside of the heart and veins to deliver defibrillation therapy. Subjects will be followed until regulatory approval is received.

Registry
clinicaltrials.gov
Start Date
September 16, 2019
End Date
January 4, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient has a Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines \[i\], or ESC guidelines \[ii\].
  • Patient is at least 18 years of age and meets age requirements per local law.
  • Patient is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.
  • \[i\] Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias. \[ii\] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliot PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal 2015 36:41 (2793-2867). https://doi.org/10.1093/eurheartj/ehv316

Exclusion Criteria

  • Patient is unwilling or unable to personally provide Informed Consent.
  • Patient has indications for bradycardia pacing \[iii\] or Cardiac Resynchronization Therapy (CRT) \[iv\] (Class I, IIa, or IIb indication).
  • Patient with an existing pacemaker, ICD, or CRT device implant or leads.
  • Patients with these medical interventions are excluded from participation in the study:
  • Prior sternotomy
  • Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space (i.e., prior mediastinal instrumentation, mediastinitis)
  • Prior abdominal surgery in the epigastric region
  • Planned sternotomy
  • Prior chest radiotherapy
  • Or any other prior/planned medical intervention not listed that precludes their participation in the opinion of the Investigator.

Outcomes

Primary Outcomes

Efficacy Outcome - Defibrillation Efficacy at Implant of the EV ICD System

Time Frame: At Implant

Each subject will demonstrate a successful defibrillation outcome if either 2 successive induced ventricular fibrillation episodes are terminated by the subject's device delivering a shock at the required energy level, or if one such episode is successfully terminated by the subject's device delivering a shock at a lower energy level. Up to 6 such episodes may be induced to test device efficacy.

Safety Outcome - Freedom From Major Complications Related to the EV ICD System and/or Procedure at 6 Months Post-implant

Time Frame: 6 Months (182 days) post implant

The primary safety endpoint is defined as a subject's first occurrence of a major complication related to the EV ICD System and/or procedure, as determined by an independent Clinical Events Committee (CEC), that occurs on or prior to 6 months (182 days) post-implant.

Study Sites (56)

Loading locations...

Similar Trials